Patents by Inventor Ilgen Mender

Ilgen Mender has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SEQUENTIAL TREATMENT OF CANCERS USING 6-THIO-dG, CHECKPOINT INHIBITORS AND RADIATION THERAPY
    Publication number: 20210290652
    Abstract: Disclosed herein are methods of treatments with a telomerase-mediated telomere-targeting drug, 6-thio-2?-deoxyguanosine (6-thio-dG), checkpoint inhibitors and/or radiation therapy for treating cancers. eads to tumor regression in innate and adaptive immune-dependent manners in syngeneic and humanized mouse cancer models.
    Type: Application
    Filed: March 12, 2021
    Publication date: September 23, 2021
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jerry Shay, Yang-Xin Fu, Ilgen Mender, Anli Zhang
  • TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS
    Publication number: 20190388453
    Abstract: The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatement of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.
    Type: Application
    Filed: June 24, 2019
    Publication date: December 26, 2019
    Applicant: The Board of Regents of the University of Texas System
    Inventors: Jerry SHAY, Ilgen MENDER, Kimberly BATTEN
  • TREATMENT OF DRUG RESISTANT PROLIFERATIVE DISEASES WITH TELOMERASE MEDIATED TELOMERE ALTERING COMPOUNDS
    Publication number: 20180036331
    Abstract: The described invention is directed toward pharmaceutical compositions and methods of using 6-mercaptopurine ribosides and analogues thereof for the treatment of cancer and other hyperproliferative diseases. The described compounds can be converted into telomere substrates in vivo and can be recognized by telomerase for incorporation into telomeres of telomerase active cells, leading to induction of cell death of the telomerase active cells.
    Type: Application
    Filed: March 23, 2017
    Publication date: February 8, 2018
    Inventors: Jerry Shay, Ilgen Mender, Kimberly Batten, Cynthia Lander